MedTrace Logo

Role of the Mespere Venus 1000 in Predicting Heart Failure Hospital Readmissions

NCT02003040 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2015-09-28

No results posted yet for this study

Summary

The purpose of this study is to investigate the utility of Venus 1000 in predicting 30-day hospital readmissions for acute decompensated heart failure. Secondary outcomes will include correlation with NT-proBNP and weight both at admission and discharge from hospital

Conditions

  • ADHF

Interventions

DEVICE

Mespere Venus 1000 CVP System

An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject. A CVP measurement is recorded at time of patient's hospital admission and discharge. CVP readings will remain concealed from the treating team.

Sponsors & Collaborators

  • Mespere Lifesciences Inc.

    lead INDUSTRY

Principal Investigators

  • Abdul Al-Hesayen, MD · Unity Health Toronto

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-04-30
Completion
2016-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02003040 on ClinicalTrials.gov